HomeNewsBusinessMarketsChartist Talks: Nifty Pharma likely scaling towards 20,000 mark in May, no overbought conditions in BHEL, says Jatin Gedia

Chartist Talks: Nifty Pharma likely scaling towards 20,000 mark in May, no overbought conditions in BHEL, says Jatin Gedia

The consolidation in Nifty Pharma index is likely to breakout on the upside, says Jatin Gedia, who is a technical research analyst at Sharekhan by BNP Paribas.

May 03, 2024 / 07:31 IST
Story continues below Advertisement
Jatin Gedia of Sharekhan by BNP Paribas
Jatin Gedia is the technical research analyst at Sharekhan by BNP Paribas

"BHEL continues to rise higher keeping the higher top and higher bottom formation intact. The upmove has been supported with volume," Jatin Gedia, technical research analyst at Sharekhan by BNP Paribas said in an interview to Moneycontrol.

On the momentum indicator, "we do not see signs of loss of momentum nor BHEL is overbought," he said.

Story continues below Advertisement

Jatin, with more than 10 years of experience in the financial services industry and expertise in technical research, feels the consolidation is likely to breakout on the upside in the Nifty Pharma index. "There is a high probability of the consolidation to complete during the month of May and scale to hit the 20,000–20,400 mark," he said.

What is your trading strategy for the next week's Nifty and Bank Nifty expiry after reading the charts? Will the index surpass 23,000 by next week?